BIVI: Bezisterim demonstrated significant symptom improvement and strong safety in Long COVID phase II
Bezisterim showed statistically significant improvements in fatigue, malaise, and cognitive symptoms among Long COVID patients with high baseline symptom burden, with a safety profile similar to placebo. Experts and patient advocates described the results as the most promising to date, supporting a…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.